Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

@article{Zhang2020SafetyTA,
  title={Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial},
  author={Y. Zhang and G. Zeng and H. Pan and Changgui Li and Ya-ling Hu and Kai Chu and W. Han and Zhen Chen and Rong Tang and Weidong Yin and X. Chen and Yuansheng Hu and X. Liu and Congbing Jiang and J. Li and Minnan Yang and Y. Song and X. Wang and Qiang Gao and F. Zhu},
  journal={The Lancet. Infectious Diseases},
  year={2020},
  volume={21},
  pages={181 - 192}
}
  • Y. Zhang, G. Zeng, +17 authors F. Zhu
  • Published 2020
  • Medicine
  • The Lancet. Infectious Diseases
  • Background With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity. Methods In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy… CONTINUE READING
    13 Citations

    Figures and Tables from this paper

    Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    • 108
    Recent drugs and vaccine candidates to tackle COVID-19
    • PDF
    Immune response scenario and vaccine development for SARS-CoV-2 infection
    The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
    • 1
    • Highly Influenced
    • PDF
    An update to “novel therapeutic approaches for treatment of COVID-19”
    • PDF
    Development and deployment of COVID-19 vaccines for those most vulnerable
    • 1
    Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells

    References

    SHOWING 1-10 OF 32 REFERENCES
    Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
    • B. Hao, Z. Chen, +12 authors J. Huang
    • Medicine
    • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
    • 2019
    • 3
    Development of an inactivated vaccine candidate for SARS-CoV-2
    • 373
    • PDF
    An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
    • 503
    • PDF
    SARS-CoV-2 vaccines in development
    • 163
    • PDF
    Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
    • X. Wang, X. Guo, +6 authors Q. Wang
    • Medicine
    • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
    • 2020
    • 31